IP Verse

Modernatx, Inc. opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Modernatx, Inc.

Patent Number:
EP2958588
Title:
Combination Of Vaccination And Inhibition Of The Pd-1 Pathway
Applicant:
CUREVAC AG
Opposition Date:
May 22, 2018
Patent Number:
EP2279254
Title:
Novel Lipid Formulations For Nucleic Acid Delivery
Applicant:
ARBUTUS BIOPHARMA CORPORATION
Opposition Date:
Apr 5, 2018

Latest patents of Modernatx, Inc. opposed by its competitors

Patent:
EP3431485
Grant Date:
Sep 4, 2024
Title:
Engineered Nucleic Acids And Methods Of Use Thereof
Oppositions:
2
Patent:
EP3359670
Grant Date:
Feb 14, 2024
Title:
Methods For Therapeutic Administration Of Messenger Ribonucleic Acid Drugs
Oppositions:
1
Patent:
EP3578652
Grant Date:
Jul 12, 2023
Title:
Ribonucleic Acid Purification
Oppositions:
1
Patent:
EP3625345
Grant Date:
May 24, 2023
Title:
Modified Messenger Rna Comprising Functional Rna Elements
Oppositions:
2
Patent:
EP3458083
Grant Date:
Nov 2, 2022
Title:
Polynucleotides Encoding Interleukin-12 (Il12) And Uses Thereof
Oppositions:
2
Patent:
EP3324979
Grant Date:
Oct 12, 2022
Title:
Infectious Disease Vaccines
Oppositions:
1
Patent:
EP3590949
Grant Date:
May 18, 2022
Title:
Ribonucleic Acids Containing N1-Methyl-Pseudouracils And Uses Thereof
Oppositions:
9
Patent:
EP3718565
Grant Date:
Apr 27, 2022
Title:
Respiratory Virus Vaccines
Oppositions:
4
Patent:
EP2791160
Grant Date:
Mar 2, 2022
Title:
Modified Nucleoside, Nucleotide, And Nucleic Acid Compositions
Oppositions:
10
Patent:
EP2922554
Grant Date:
Feb 23, 2022
Title:
Terminally Modified Rna
Oppositions:
1

Competitors of Modernatx, Inc.

BIONTECH SE

WITHERS & ROGERS LLP

PFIZER INC.

Want to track Modernatx, Inc.?

Feel free to send us a message here and we will get back to you